SCHEMBL6152074

SCHEMBL6152074

COC(=O)c1ccc(C(=O)OC)c(S(=O)(=O)Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.56
HSD17B10 Q99714 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
ALDH1A1 P00352 10/20 0.56
HPGD P15428 6/20 0.56
GAA P10253 3/20 0.56
ATM Q13315 3/20 0.56
MAPT P10636 2/20 0.56
CASP1 P29466 2/20 0.56
CASP7 P55210 2/20 0.56
GLA P06280 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.50
CYP1A2 P05177 1/20 0.50
TSHR P16473 1/20 0.50
CYP2C19 P33261 1/20 0.50
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
CA12 O43570 1/20 0.47
CA7 P43166 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9324149 0.87 KDM4E (0.53) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD
SCHEMBL3339517 0.85 KDM4E (0.58) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD
SCHEMBL1863796 0.83 KDM4E (0.56) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD
SCHEMBL669263 0.83 ALDH1A1 (0.50) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD
Potassium SCHEMBL31619359 0.83 KDM4E (0.56) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD
SCHEMBL5452555 0.83 ABL1 (0.58) KDM4EHSD17B10SMN1; SMN2ALDH1A1MAPT
SCHEMBL4602708 0.83 KDM4E (0.56) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD
SCHEMBL1495720 0.83 ALDH1A1 (0.65) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD
Cesium SCHEMBL4605888 0.83 KDM4E (0.56) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD
SCHEMBL1868219 0.83 KDM4E (0.56) KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3521380-B1 COLORING COMPOSITION, INK FOR INKJET RECORDING, INKJET RECORDING METHOD, AND INKJET PRINTER CARTRIDGE FUJIFILM CORP (JP) 2023-03-08 EP disclosed
US-20230024859-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-01-26 US disclosed
CN-108430981-B Process for preparing 1,1, 3-trioxo-1, 2-benzothiazole-6-carboxamides 阿达玛阿甘股份有限公司 2022-05-10 CN disclosed
WO-2020254697-A1 FUSED 1,2 THIAZOLES AND 1,2 THIAZINES WHICH ACT AS NL3P3 MODULATORS AC IMMUNE SA (CH) 2020-12-24 WO disclosed
EP-3397620-B1 PROCESS FOR PREPARING 1.1.3-TRIOXO-1.2-BENZOTHIAZOLE-6-CARBOXAMIDE ADAMA AGAN LTD (IL) 2020-11-25 EP disclosed
US-10745577-B2 Aqueous solution, coloring composition, ink jet recording ink, ink jet recording method, and ink cartridge FUJIFILM CORPORATION (JP) 2020-08-18 US disclosed
CN-109790395-B Coloring composition, ink for inkjet recording, inkjet recording method, and ink cartridge for inkjet printer 富士胶片株式会社 2020-08-11 CN disclosed
US-10633352-B2 Process for preparing 1,1,3-trioxo-1,2-benzothiazole-6-carboxamide ADAMA AGAN LTD. (IL) 2020-04-28 US disclosed
EP-3521380-A1 COLORING COMPOSITION, INK FOR INKJET RECORDING, INKJET RECORDING METHOD, AND INKJET PRINTER CARTRIDGE Fujifilm Corporation (JP) 2019-08-07 EP disclosed
EP-3521377-A1 AQUEOUS SOLUTION, COLORANT COMPOSITION, INKJET RECORDING INK, INKJET RECORDING METHOD, AND INK CARTRIDGE FUJIFILM Corporation (JP) 2019-08-07 EP disclosed
US-20190218408-A1 AQUEOUS SOLUTION, COLORING COMPOSITION, INK JET RECORDING INK, INK JET RECORDING METHOD, AND INK CARTRIDGE FUJIFILM CORPORATION (JP) 2019-07-18 US disclosed
CN-109790395-A Coloring composition, ink for inkjet recording, inkjet recording method, and ink cartridge for inkjet printer 富士胶片株式会社 2019-05-21 CN disclosed
US-20190002419-A1 PROCESS FOR PREPARING 1,1,3-TRIOXO-1,2-BENZOTHIAZOLE-6-CARBOXAMIDE ADAMA AGAN LTD. (IL) 2019-01-03 US disclosed
EP-3397620-A1 PROCESS FOR PREPARING 1.1.3-TRIOXO-1.2-BENZOTHIAZOLE-6-CARBOXAMIDE Adama Agan Ltd. (IL) 2018-11-07 EP disclosed
CN-108430981-A Process for preparing 1,1, 3-trioxo-1, 2-benzothiazole-6-carboxamides 阿达玛阿甘股份有限公司 2018-08-21 CN disclosed
WO-2017115134-A1 PROCESS FOR PREPARING 1.1.3-TRIOXO-1.2-BENZOTHIAZOLE-6-CARBOXAMIDE ADAMA AGAN LTD. (IL) 2017-07-06 WO disclosed
EP-1028949-B1 CARBAMOYLPHENYLSULFONYL UREAS, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION AS HERBICIDES AND PLANT GROWTH REGULATORS BAYER CROPSCIENCE GMBH (DE) 2005-03-23 EP disclosed
US-6228808-B1 BROAD SPECTRUM PRE-EMERGENCE OR POST-EMERGENCE HERBICIDES HOECHST SCHERING AGREVO GMBH (DE) 2001-05-08 US disclosed
EP-1028949-A1 CARBAMOYLPHENYLSULFONYL UREAS, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION AS HERBICIDES AND PLANT GROWTH REGULATORS Aventis CropScience GmbH (DE) 2000-08-23 EP disclosed
WO-1999023079-A1 CARBAMOYLPHENYLSULFONYL UREAS, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION AS HERBICIDES AND PLANT GROWTH REGULATORS AVENTIS CROPSCIENCE GMBH (DE) 1999-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633352-B2 Process for preparing 1,1,3-trioxo-1,2-benzothiazole-6-carboxamide SAT1, H1-0, H1-2 KDM4E 1117/4885HSD17B10 2247/4885SMN1; SMN2 1815/4885
US-20230024859-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 KDM4E 4507/4885HSD17B10 932/4885SMN1; SMN2 2580/4885
US-20190002419-A1 PROCESS FOR PREPARING 1,1,3-TRIOXO-1,2-BENZOTHIAZOLE-6-CARBOXAMIDE SAT1, H1-0, H1-2 KDM4E 1117/4885HSD17B10 2247/4885SMN1; SMN2 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.